RT @hausmannMD: Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A. In patients with psoriatic arthritis, ixekizuma…
Tweet Content
Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A.
In patients with psoriatic arthritis, ixekizumab was better than adalimumab in treating skin disease (PASI 100).
Similar improvements in joint disease (ACR20/50/70).
Dr. Josef Smolen #ACR19 @RheumNow https://t.co/BriY8o10Hq
Show on Archive Page
On
Display in Search Results
On